A carregar...
Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in Autism Spectrum Disorder
PURPOSE: Selective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with Autism Spectrum Disorder (ASD), but there are individual differences in treatment response and tolerability. CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and w...
Na minha lista:
| Publicado no: | Pharmacogenet Genomics |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4591203/ https://ncbi.nlm.nih.gov/pubmed/26313485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000173 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|